# A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

> **NCT07499700** · PHASE2,PHASE3 · RECRUITING · sponsor: **Bio-Thera Solutions** · enrollment: 192 (estimated)

## Conditions studied

- Minimal Change Disease (MCD)
- Focal Segmental Glomerulosclerosis (FSGS)

## Interventions

- **DRUG:** BAT4406F
- **OTHER:** Placebos

## Key facts

- **NCT ID:** NCT07499700
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-26
- **Primary completion:** 2030-10-26
- **Final completion:** 2030-11-26
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07499700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07499700, "A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07499700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*